Login / Signup

Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy.

Ya-Qian XuYan WangChenwei YuanXiaonan ShengRui ShaHuijuan DaiShan ZhangYaohui WangYanping LinLiheng ZhouShuguang XuJie ZhangWenjin YinJinsong Lu
Published in: Therapeutic advances in medical oncology (2020)
Our study suggests that EPIC1 may be a promising biomarker for both neoadjuvant chemosensitivity and long-term clinical outcomes in breast cancer, specifically in the HorR-positive premenopausal subgroup. It may also help identify candidate responders and determine treatment strategies.
Keyphrases
  • neoadjuvant chemotherapy
  • locally advanced
  • lymph node
  • rectal cancer
  • sentinel lymph node
  • squamous cell carcinoma
  • radiation therapy
  • postmenopausal women
  • randomized controlled trial